PredictImmune’s Prognostic Biomarker Test for IBD to feature in Platform Presentations at Upcoming Conferences
Cambridge, UK, 17th September 2018: PredictImmune’s first product, a prognostic biomarker test for IBD will be the subject of two key presentations at upcoming conferences in the coming weeks. The presentations will be an opportunity to hear about ground-breaking research currently being carried out in the field of IBD at the University of Cambridge.
27th-28th September, Congress Centre Kursaal, Interlaken, Switzerland
Dr. James Lee will present ‘Practical implications of genetics in IBD’ as part of the IBD Session from 8:00-10:00 am, on Thursday 27th September. This is an excellent opportunity to catch up on the latest developments in IBD, including the use of the prognostic biomarkers to drive personal medicine.
The Falk Foundation, Symposium 213: Tailored Therapies for IBD: A Look into the Future
October 5 – 6, Milan Marriott Hotel, Milan, Italy
The Falk Foundation offers a broad spectrum of events promoting the exchange of knowledge, as well as postgraduate courses in gastroenterology and hepatology. The International symposia provide scientists and doctors with a first-class platform for exchanging knowledge in pure and clinical research.
Dr. Nurulamin Noor, will be presenting a poster entitled “PROFILE trial: PRedicting Outcomes For Crohn’s dIsease using a moLecular biomarker” on Friday 4th October. This poster has been selected as one of the presentations of distinction by the organising committee of the meeting.